The Chain Consists Of Two Or More Carbons Which Are Unsubtituted Or Have Acyclic Hydrocarbyl Substituents Only Patents (Class 514/654)
-
Patent number: 7822474Abstract: Methods and kits are provided for determining an increased likelihood of the occurrence of a cardiac arrhythmia, myocardial ischemia, congestive heart failure and other diseased conditions of the heart. The methods and kits comprise measuring serum NGF levels in a subject and detecting increases in NGF levels over baseline. The methods may further comprise initiating preventive therapy in response to a detected increase in serum NGF levels.Type: GrantFiled: November 29, 2006Date of Patent: October 26, 2010Assignee: Cedars-Sinai Medical CenterInventor: Peng-Sheng Chen
-
Publication number: 20100267678Abstract: The present invention is drawn to adhesive solidifying formulations, methods of drug delivery, and solidified layers for dermal delivery of a drug. The formulation can include a drug, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system comprising at least one volatile solvent, and a non-volatile solvent system comprising at least one non-volatile solvent, wherein at least one non-volatile solvent is a flux-enabling non-volatile solvent(s) capable of facilitating the delivery of the drug at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated.Type: ApplicationFiled: April 16, 2010Publication date: October 21, 2010Inventors: Jie Zhang, Kevin S. Warner, Sanjay Sharma
-
Publication number: 20100260833Abstract: The invention relates to a solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. The agent forms, when a necessary minimum amount of an aqueous liquid is added, on the basis of an extract obtained from the administration form, a preferably injectable gel that remains visually distinct when introduced into another quantity of an aqueous liquid.Type: ApplicationFiled: June 24, 2010Publication date: October 14, 2010Applicant: GRUNENTHAL GMBHInventors: Johannes BARTHOLOMÄUS, Heinrich Kugelmann
-
Publication number: 20100261713Abstract: Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse; and an effective amount of an irritant to impart an irritating sensation to an abuser upon administration of said dosage form after tampering.Type: ApplicationFiled: April 20, 2010Publication date: October 14, 2010Applicant: Purdue Pharma L.P.Inventor: Richard SACKLER
-
Publication number: 20100256116Abstract: A method of screening a subject for a serotonergic neurotransmission dysregulation disorder comprises detecting the presence or absence of an Tph2 mutation in the subject; and then determining that the subject is at increased risk of a serotonergic neurotransmission dysregulation disorder due to the presence or absence of the Tph2 mutation.Type: ApplicationFiled: July 28, 2009Publication date: October 7, 2010Inventors: Marc G. Caron, Xiaodong Zhang, Martin Beaulieu, Raul R. Gainetdinov, Tatiana D. Sotnikova, Ranga R. Krishnan, David A. Schwartz, Redford B. Williams, Lauranell Burch
-
Publication number: 20100249242Abstract: The present invention is directed to a method of reducing the occurrence of neuronal cell damage, including death, caused by transient cerebral hypoxia and/or ischemia. The method comprises the steps of: diagnosing a subject having a transient cerebral hypoxic and/or ischemic condition; and within 16 hours after onset of the condition, administering to the subject a neuroprotective amount of a pharmaceutical agent. The pharmaceutical agent is preferably selected from the group consisting of: a central nervous system stimulant (CNSS), monoamine neurotransmitter, monoamine oxidase inhibitor (MAOI), tricyclic antidepressant (TCA), or a combination thereof. Preferred agents include amphetamines, methamphetamine, methylphenidate, methylenedioxymethamphetamine, or a combination thereof.Type: ApplicationFiled: August 15, 2007Publication date: September 30, 2010Inventors: David J. Poulsen, Thomas Frederick Rau
-
Publication number: 20100249045Abstract: The present invention is in the field of oral, abuse resistant pharmaceutical compositions of opioid agonists, extended release pharmaceutical compositions of opioid agonists and extended release abuse resistant pharmaceutical compositions of opioid agonists and the use thereof. The present invention is also directed to extended release pharmaceutical compositions and the use thereof for preventing or minimizing the risk of abuse and/or toxicity from either intentional or unintentional tampering. The present invention is further directed at a method of preventing or minimizing the risk of abuse and/or toxicity from either intentional or unintentional tampering.Type: ApplicationFiled: April 26, 2008Publication date: September 30, 2010Applicant: THERAQUEST BIOSCIENCES, INC.Inventor: Najib Babul
-
Publication number: 20100227933Abstract: The invention described herein provides a fast dispersing oral solid dosage form containing monoamine oxidase B inhibitor (MAO-B inhibitor) as the active ingredient, and method of treating disease therewith, such as Parkinson's disease. In one embodiment, the monoamine oxidase B inhibitor selegiline or its analogue can be the sole active ingredient in the composition administered. The dosage form composition is formulated to promote absorption through the buccal, sublingual, pharyngeal and/or esophageal mucous membrane tissue, such that at least 5% of the active ingredient is absorbed within one minute of placement in the oral cavity, as determined by a buccal absorption test. Monoamine oxidase B inhibitor compounds administered in accordance with the invention decrease the amount of undesirable metabolites associated with first pass effect of selegiline, for example, such as amphetamine and methamphetamine.Type: ApplicationFiled: May 18, 2010Publication date: September 9, 2010Inventors: Francesca Mary Brewer, Edward Stewart Johnson, Anthony Clarke
-
Publication number: 20100203153Abstract: The present invention is a composition composed of a therapeutic agent encapsulated in a copolymer of an N-alkylacrylamide, a vinyl monomer, and a polyethylene glycol (PEG) conjugate and a method for using the same in the treatment or prevention of a disease or condition.Type: ApplicationFiled: April 19, 2010Publication date: August 12, 2010Inventors: Vinod D. Labhasetwar, Sanjeeb K. Sahoo, Maram K. Reddy
-
Publication number: 20100197742Abstract: A pharmaceutical formulation comprising one or more active pharmaceutical ingredients (APIs) suitable for intraoral uptake, that comprises cocoa powder, a process for manufacturing the formulation and use of the formulation for medical treatment.Type: ApplicationFiled: February 22, 2010Publication date: August 5, 2010Inventors: Fredrik Nicklasson, Kristina Thyresson, Nils-Olof Lindberg, Alice C. Martino, Katarina Lindell
-
Publication number: 20100197661Abstract: The present invention provides methods for treating neurological diseases and disorders. Compounds that replace or enhance the function of SMN or alleviate or reduce a phenotype of cells with low SMN protein levels are provided. Screening methods and kits for identifying such compounds also are provided.Type: ApplicationFiled: March 23, 2010Publication date: August 5, 2010Inventors: Gideon Dreyfuss, Jin Wang
-
Publication number: 20100197626Abstract: The present invention provides various biomarkers of depression. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of depression, methods of determining predisposition to depression, methods of monitoring progression/regression of depression, methods of assessing efficacy of compositions for treating depression, methods of screening compositions for activity in modulating biomarkers of depression, methods of treating depression, as well as other methods based on biomarkers of depression.Type: ApplicationFiled: May 8, 2007Publication date: August 5, 2010Inventors: Lisa A. Paige, Matthew W. Mitchell, Anne Evans, Don Harvan
-
Patent number: 7767710Abstract: A method and composition for treating osteoarthritis with ion-channel regulators is disclosed. The ion-channel regulators are used alone or in combination with other osteoarthritis treatment agents, including but not limited to injectable agents such as viscosupplements and steroids. A composition comprising one or more ion-channel regulator(s) and one or more osteoarthritis treatment agent(s) is also disclosed.Type: GrantFiled: May 25, 2005Date of Patent: August 3, 2010Assignee: Calosyn Pharma, Inc.Inventor: David D. Waddell
-
Publication number: 20100190752Abstract: A composition of matter comprising in combination as component (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound, and as component (b) at least one antiepileptic, a pharmaceutical formulation and a dosage form comprising said composition of matter, and a method of treating pain, e.g. neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, whereby component (a) may be administered before or after component (b) and whereby components (a) or (b) are administered to the mammal either via the same or a different pathway of administration.Type: ApplicationFiled: January 26, 2010Publication date: July 29, 2010Applicant: Gruenenthal GmbHInventors: Klaus Schiene, Petra Bloms-Funke, Thomas Christoph
-
Publication number: 20100189786Abstract: A crystalline salt of 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-methyl-phenol with (2R,3R)-2,3-dihydroxybutanedioic acid, known under the name R-tolterodine tartarate, wherein: a) at least 90% of all crystals are present in a size smaller than 30 ?m, b) at least 40% of crystalline matter are smaller than 250 ?m, c) the maximum size of crystals does not exceed 800 ?m, d) the salt contains less than 0.1 weight % of the undesirable enantiomer S-tolterodine tartarate, e) analytical test for sulfate ashes (Pharm. Eur.) provides a value lower than 0.1%. The method of its preparation involves at least one crystallization from water. A pharmaceutical composition containing tolterodine or its pharmaceutically acceptable salts further contains a filler, a disintegrant and a lubricant, said composition being free of ions of alkaline earth metals.Type: ApplicationFiled: August 9, 2007Publication date: July 29, 2010Inventors: Martin Svoboda, Josef Jampilek, Martina Kacirkova, Vaclav Tomasek, Mikulas Lehocky, Ludmila Hejtmankova, Vaclav Vosatka
-
Publication number: 20100189698Abstract: A method for the treatment and/or prophylaxis of a neurological and/or neuropsychiatric disorder associated with altered dopamine function comprising administering to the eye of a patient in need thereof an effective amount of an agent that modulates neurotransmitter production or function.Type: ApplicationFiled: June 30, 2008Publication date: July 29, 2010Applicant: CLARENCEW PTY LTDInventor: Gregory Lynn Willis
-
Patent number: 7763603Abstract: Provided herein methods of screening for potential antidepressant compounds effective to increase production of cellular CDP-diacylglycerol and synthesis of inositol phospholipid in depression-related areas of the brain. Also, provided are methods of diagnosing and treating depressive or mood disorders in a subject by administering these screened antidepressant compounds. Further provided is a method of determining the therapeutic efficacy of an antidepressant drug regimen by comparing the ratio of CDP-diacylglycerol/inositol phosphate after treatment to a basal ratio in a subject.Type: GrantFiled: August 9, 2007Date of Patent: July 27, 2010Inventors: Kimberly R. Tyeryar, Ashiwel S. Undie
-
Publication number: 20100179111Abstract: The invention provides compounds of formula I and compositions thereof. The invention further provides methods of using the compounds and compositions. The compounds of the invention can provide high affinity binding to sigma-1 receptors in a mammal. The compounds can exhibit selectivity for the sigma-1 receptor over the sigma-2 receptor. The compounds and compositions of the invention can also be used to treat conditions that involve the sigma-1 receptor, such as addiction, cardiovascular conditions, and cancer, for example, cancer of the breast, lung, prostate, ovarian, colorectal, or the CNS.Type: ApplicationFiled: November 18, 2009Publication date: July 15, 2010Applicant: WARF - Wisconsin Alumni Research FoundationInventors: Arnold E. Ruoho, Abdol R. Hajipour, Uyen B. Chu, Dominique A. Fontanilla
-
Publication number: 20100172959Abstract: A dermal or transdermal therapeutic system comprising a reservoir that contains at least one active substance, an active substance-permeable membrane which delimits the active-substance reservoir, and a closing layer. The closing layer is impermeable to the active substance at a temperature lying below the skin temperature while being permeable at skin temperature and above.Type: ApplicationFiled: December 31, 2009Publication date: July 8, 2010Applicant: ACINO AGInventors: Heike HAUSNER, Sebastian BRAUN, Heiko SPILGIES
-
Publication number: 20100166864Abstract: The present invention relates to an oral pulse release pharmaceutical composition, which comprises a polymer matrix core, wherein at least one pharmaceutically active ingredient is distributed within the core and on the outer surface of the core. Amphetamine salts, among a number of other pharmaceutically active ingredients, can be formulated as a pharmaceutical composition described herein. The present invention also provides a method for preparing an immediate release component on a solid pharmaceutical formulation.Type: ApplicationFiled: March 22, 2006Publication date: July 1, 2010Applicant: MALLINCKRODT INC.Inventors: Ashwini Gadre, Mark R. Benmuvhar, Brian Kai-Ming Cheng, Vishal Gupta, Cliff J. Herman
-
Publication number: 20100159004Abstract: The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment.Type: ApplicationFiled: August 4, 2009Publication date: June 24, 2010Inventors: Maryka Quik, Donato Di Monte, J. William Langston
-
Publication number: 20100160447Abstract: A hitherto unknown crystalline form of (?)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence.Type: ApplicationFiled: December 10, 2009Publication date: June 24, 2010Applicant: Gruenenthal GmbHInventors: Andreas Fischer, Helmut Buschmann, Michael Gruss, Dagmar Lischke
-
Publication number: 20100144691Abstract: Methods are provided for treating a subject for a fertility condition. In accordance with the subject methods, at least a portion of a subject's autonomic nervous system is modulated to increase the sympathetic activity/parasympathetic activity ratio in a manner that is effective to treat the subject for the condition. Embodiments of the subject invention include modulating a subject's autonomic nervous system using electrical energy and/or one or more pharmacological agents. The subject methods find use in the treatment of a variety of different fertility conditions. Also provided are kits for use in practicing the subject methods.Type: ApplicationFiled: January 22, 2010Publication date: June 10, 2010Inventors: ANTHONY JOONKYOO YUN, Patrick Yuarn-Bor Lee
-
Publication number: 20100144660Abstract: The present invention provides for the use of N,N-diethyl-2-[-4-(phenylmethyl)-phenoxy]ethanamine monohydrochloride (DPPE) in cancer therapy. DPPE is used in the treatment of patients having, or suspected of having, an aggressive cancer. The present invention further provides for the use of DPPE in the treatment of a patient suspected of having an existing cancer, wherein the use follows a surgery for treatment of a primary cancer that is estrogen-receptor negative. Also provided are pharmaceutical compositions comprising DPPE for use in the treatment of patients having, or suspected of having, an aggressive cancer and pharmaceutical kits comprising such compositions.Type: ApplicationFiled: October 19, 2009Publication date: June 10, 2010Applicants: YM Biosciences Inc., University of ManitobaInventors: Mark VINCENT, Lorn J. Brandes
-
Publication number: 20100144886Abstract: The present invention is directed to methods comprising administering a composition comprising a therapeutically effective amount of (R)-verapamil, a derivative thereof, or a pharmaceutically acceptable salt thereof, wherein the composition treats, prevents and/or manages at least one condition having MT1 receptor, 5-HT2B receptor and L-type calcium channel activity and releases the (R)-verapamil, a derivative thereof or a pharmaceutically acceptable salt thereof to exhibit a co-primary activity on the MT1 receptor, the 5-HT2B receptor, and the L-type calcium channel.Type: ApplicationFiled: February 22, 2010Publication date: June 10, 2010Applicant: AGI Therapeutics Research LimitedInventors: John DEVANE, Jojn KELLY, Mary MARTIN
-
Publication number: 20100137333Abstract: An antifungal composition is provided according to the present invention. The antifungal composition comprises an effective amount of an antifungal component to provide antifungal properties to skin tissue, an effective amount of a skin bonding polymer component to provide a sustained release of the antifungal component over a prolonged period of time after application of the antifungal treatment composition to skin tissue, and water. A method for using the antifungal composition is provided.Type: ApplicationFiled: October 19, 2007Publication date: June 3, 2010Inventor: James A. Roszell
-
Patent number: 7728040Abstract: Polyamine compounds, method of synthesis and method of use for anti-cancer purposes, for enhancing the activity of existing anti-cancer drugs, as well as, for inhibiting N-Methyl-D-Aspartate (NMDA) receptors found in neurotransmission systems are provided. Certain polyamine motifs have been identified that can be attached to toxic agents to facilitate their access to cancer cells as well as polyamine compounds of surprising cytotoxicity with selectivity in killing cancer cells, and surprising utility in the treatment of Alzheimer's disease and brain stroke. It includes an illustrative conjugate system with examples of a triamine or a tetraamine appended to a cytotoxic agent. Included is a general strategy to enhance cell uptake by attaching a polyamine vectoring system with an example of a triamine vector attached to an existing anti-cancer drug to improve its chemotherapeutic potency.Type: GrantFiled: May 9, 2008Date of Patent: June 1, 2010Assignee: University of Central Florids Research Foundation, Inc.Inventor: Otto Phanstiel
-
Publication number: 20100130603Abstract: A medicament for prophylactic and/or therapeutic treatment of a dermatosis resulting from excessively advanced keratinization, such as non-hereditary inflammatory keratosis and hereditary congenital keratosis, which comprises a substance selected from the group consisting of a cannabinoid agonist and a vanilloid agonist as an active ingredient.Type: ApplicationFiled: March 7, 2008Publication date: May 27, 2010Applicant: KYOTO UNIVERSITYInventor: Kenzo Takahashi
-
Publication number: 20100130422Abstract: A cocoa extract obtainable by the extraction of non-defatted cocoa beans which have not been fermented or have been allowed to ferment for no more than three days, having a polyphenol content of more than 25% by weight, may be used in the treatment or alleviation of obesity.Type: ApplicationFiled: April 24, 2008Publication date: May 27, 2010Inventors: Herwig Bernaert, Leen Allegaert
-
Publication number: 20100119525Abstract: The present invention relates to a method for prolonging longevity using and NPC1L1 antagonist. The present invention also provides a method for reducing weight in an individual who consumes a high-fat diet using an NPC1L1 antagonist.Type: ApplicationFiled: August 1, 2006Publication date: May 13, 2010Applicant: MOUNT SINAI SCHOOOL OF MEDICINE OF NEW YORK UNIVERSITYInventor: Yiannis Ioannou
-
Publication number: 20100113379Abstract: The present invention relates to the induction of autophagy via mTOR independent pathways which modulated intracytosolic cAMP levels. In some embodiments, autophagy may be induced in a cell by reducing intracytosolic cAMP levels, for example using a cAMP antagonist, such as clonidine. This may be useful, for example in the treatment of neurodegenerative disorders or pathogen infections.Type: ApplicationFiled: February 14, 2008Publication date: May 6, 2010Inventors: David Rubinsztein, Sovan Sarkar, Andrea Williams
-
Publication number: 20100105672Abstract: Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.Type: ApplicationFiled: August 3, 2009Publication date: April 29, 2010Inventors: Philip A. Swain, Victoria C. Schad, Julia L. Greenstein, Mark A. Exley, Barbara S. Fox, Stephen P. Powers
-
Publication number: 20100105637Abstract: The invention involves sustained-release pharmaceutical compositions containing a water-soluble ionic small molecule pharmaceutical agent complexed with an oppositely charged surfactant, particularly a natural bile surfactant. The complexes are sustained-release ionic complexes. The complexes release the ionic pharmaceutical agents into aqueous solution slowly and with zero-order kinetics. Thus, they can be formulated into sustained-release pharmaceutical compositions.Type: ApplicationFiled: October 22, 2009Publication date: April 29, 2010Inventor: Cherng-ju Kim
-
Publication number: 20100105765Abstract: The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss. The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.Type: ApplicationFiled: January 6, 2010Publication date: April 29, 2010Inventor: Thomas Najarian
-
Publication number: 20100104621Abstract: The present disclosure relates to methods and drug delivery systems for treating diseases involving inflammation, including Attention Deficit Hyperactivity Disorder (ADHD) by administering a CNS stimulant to a patient in need thereof so as to maintain steady state serum drug levels that remain therapeutically effective for about 24 and ½ to about 25-27 hours or longer after administration to maintain a constant steady state between doses of medication. The method is employed to restore normal catecholamine levels throughout the day without over-stimulating or under-stimulating the patient. Additionally, the present method of treating inflam?na?ion3 including ADHD, provides, for example, dosing once a day or once a week. The present method also addresses other aspects of the disease, for example, defective P-5-P synthesis, ehminating interleukins and free radicals, and correction of Amino acids, the endocrine system and inflammation.Type: ApplicationFiled: February 5, 2008Publication date: April 29, 2010Applicant: CONNECTED HEALTH SYSTEMS, LLCInventor: Ralph E. Waldo
-
Publication number: 20100104624Abstract: Described here are compositions and methods for treating side-effects of vasodilator therapy. The compositions may include both a vasodilator and a side-effect alleviating agent in a single dosage form. Alternatively, the vasodilator and side-effect alleviating agent may be formulated separately, each in its own dosage form. The compositions may be packaged as kits for use with various medical conditions.Type: ApplicationFiled: June 11, 2009Publication date: April 29, 2010Inventors: Peter LANGECKER, Bryan T. Oronsky
-
Publication number: 20100093865Abstract: Provided are sulphur-linked compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.Type: ApplicationFiled: September 2, 2009Publication date: April 15, 2010Applicant: Acucela, Inc.Inventors: Ian L. Scott, Vladimir A. Kuksa, Ryo Kubota
-
Publication number: 20100092559Abstract: The present invention provides a method of promoting bone growth in a subject in need thereof, by administering to the subject a therapeutically effective amount of a compound of Formula I. The present invention also provides methods for the treatment of renal disease and cancer.Type: ApplicationFiled: October 1, 2009Publication date: April 15, 2010Applicant: OsteoGeneX Inc.Inventors: Debra Ellies, William Rosenberg
-
Publication number: 20100092479Abstract: The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E).Type: ApplicationFiled: August 17, 2009Publication date: April 15, 2010Applicant: CombinatoRx (Singapore) Pte. Ltd.Inventors: Lisa M. Johansen, Christopher M. Owens
-
Publication number: 20100092454Abstract: What is described is a use of an antidepressant compound, preferably belonging to the class of selective serotonin reuptake inhibitors (SSRI), for regenerating the integumentary system and/or for stimulating the growth, the original trophism and/or original pigmentation of the corresponding cutaneous appendages, particularly body hair and/or head hair, in mammals. For this purpose, the antidepressant can be formulated in a cosmetic preparation, a pharmaceutical composition, a medical device, or in the form of a culture medium, alone or in combination with a further active ingredient such as a proteolytic enzyme and/or a vitamin.Type: ApplicationFiled: December 20, 2007Publication date: April 15, 2010Inventors: Enrico De Vivo, Antonio Ponzetto, Chiara Cesano, Luisa Gennero, Gianfranco Merizzi, Emanuella Morra
-
Publication number: 20100087768Abstract: A monolithic device for transdermal administration of an active pharmaceutical ingredient which is selected from propargylamines and rivastigmine and is liquid at 25° C., has an adhesive matrix layer which includes the active ingredient in an acrylic polymer pressure sensitive adhesive without cross-linker agent containing a metal atom, the adhesive having a shear value of between 1.5 and 15 hours, and further includes a non-volatile coadjuvant selected from squalene and triethylcitrate present in the layer in an amount of 1 to 15 wt %. The combination provides good release of the drug in use, reduces loss of the drug during a drying step in manufacture, reduces chemical interaction of the layer with the drug and achieves low level of skin irritation.Type: ApplicationFiled: July 9, 2009Publication date: April 8, 2010Inventors: Paula FORLANO, Alejandro Scasso, Francisco Stefano
-
Publication number: 20100076087Abstract: Disclosed herein are methods for the reduction of inter-patient variability of a drug, such as in one or more parameters including half-life (t1/2), maximum plasma concentration (Cmax), time at maximal plasma concentration (Tmax), area under the time-versus-concentration curve (AUC). Also provided are methods of reducing side effects associated with drugs.Type: ApplicationFiled: April 13, 2009Publication date: March 25, 2010Applicant: Auspex Pharmaceuticals, Inc.Inventors: Thomas G. Gant, Sepehr Sarshar
-
Publication number: 20100076088Abstract: Crystalline form IV of the compound of formula (I): characterised by its powder X-ray diffraction diagram. Medicinal products containing the same which are useful in the treatment of melatoninergic disorders.Type: ApplicationFiled: November 24, 2009Publication date: March 25, 2010Applicant: LES LABORATOIRES SERVIERInventors: Gérard Coquerel, Julie Linol, Jean-Claude Souvie
-
Publication number: 20100063148Abstract: A composition of matter comprising in combination as component (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound, and as component (b) at least one antiepileptic, a pharmaceutical formulation and a dosage form comprising said composition of matter, and a method of treating pain, e.g. neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, whereby component (a) may be administered before or after component (b) and whereby components (a) or (b) are administered to the mammal either via the same or a different pathway of administration.Type: ApplicationFiled: September 4, 2009Publication date: March 11, 2010Applicant: GRUENENTHAL GmbHInventors: Thomas Christoph, Klaus Schiene, Petra Bloms-Funke
-
Publication number: 20100040690Abstract: Transdermal drug delivery patches and methods of their production are described. The patches can be made such that the accommodate highly plasticizing drugs such as selegiline and/or the use of protonated forms of various drugs.Type: ApplicationFiled: October 22, 2009Publication date: February 18, 2010Inventors: Sharad K. Govil, Ludwig J. Weimann
-
Publication number: 20100035859Abstract: A method of treatment for the prevention or therapy of a protein aggregation disease includes the administration in combination of a first active medicament and a second active medicament, wherein the first active medicament is active to impede aggregation of amyloid protein and the second active medicament is active to disaggregate previously formed aggregates of amyloid protein.Type: ApplicationFiled: January 30, 2008Publication date: February 11, 2010Applicant: PAD Pharma LimitedInventors: Stuart Mark Wilson, Christopher John Stanley
-
Publication number: 20100029665Abstract: The present invention provides novel methods and compositions for the treatment and prevention of headaches, vascular headaches, migraine headaches, cluster headaches, and migraine. One of the headaches, vascular headaches, migraine headaches, cluster headaches, and migraine treated by the methods and compositions of the invention is migraine.Type: ApplicationFiled: April 8, 2009Publication date: February 4, 2010Inventors: Laurence R. Meyerson, Gregory T. Went, Timothy J. Fultz, Timothy S. Burkoth
-
Publication number: 20100022658Abstract: Cognitive impairments in humans with multiple sclerosis are treated and cognition is improved with an amphetamine compound. In one embodiment, the method includes administering an l-amphetamine compound. In another embodiment, the method includes administering an l-methamphetamine compound.Type: ApplicationFiled: August 6, 2008Publication date: January 28, 2010Applicant: Cognition Pharmaceuticals LLCInventors: Mel H. Epstein, Kjesten A. Wiig
-
Publication number: 20100022659Abstract: The invention provides methods and compositions for the treatment of dementia-related conditions, such as Parkinson's disease and Alzheimer's disease.Type: ApplicationFiled: June 24, 2009Publication date: January 28, 2010Inventors: Laurence R. Meyerson, Gregory T. Went, Timothy J. Fultz
-
Publication number: 20100015224Abstract: The present invention is concerned with a system for spatially and temporally programmable delivery of an active agent. When administered orally, the System can be retained in the gastric region for a prolonged period of time. It comprises of a core (I), one or more layers (II, IV, V) coated over the core and a preformed hollow space (III). The invention also concerns with a process for preparation of the System and a method for treating/preventing diseases, by administering to a subject in need thereof, the System of the invention.Type: ApplicationFiled: September 3, 2007Publication date: January 21, 2010Inventors: Amarjit Singh, Sarabjit Singh, Shivanand Puthli, Rajendra Tandale